Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OneMedNet (ONMD) Research & Development (2022 - 2025)

OneMedNet has reported Research & Development over the past 4 years, most recently at $443000.0 for Q4 2025.

  • Quarterly Research & Development rose 30.29% to $443000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 2.05% year-over-year, with the annual reading at $1.5 million for FY2025, 3.27% up from the prior year.
  • Research & Development was $443000.0 for Q4 2025 at OneMedNet, up from $323000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $880638.0 in Q4 2022 and troughed at $298000.0 in Q3 2024.
  • The 4-year median for Research & Development is $405000.0 (2023), against an average of $454433.7.
  • Year-over-year, Research & Development crashed 43.34% in 2023 and then skyrocketed 30.29% in 2025.
  • A 4-year view of Research & Development shows it stood at $880638.0 in 2022, then crashed by 43.34% to $499000.0 in 2023, then tumbled by 31.86% to $340000.0 in 2024, then skyrocketed by 30.29% to $443000.0 in 2025.
  • Per Business Quant, the three most recent readings for ONMD's Research & Development are $443000.0 (Q4 2025), $323000.0 (Q3 2025), and $382000.0 (Q2 2025).